Marisa Wexler, MS, senior science writer —

Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines of therapy and failed to respond to standard Revlimid (lenalidomide). That’s according to the first data analysis, at nearly 1.5 years of follow-up,…

Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost three years, on average, in people with relapsed or refractory — hard-to-treat — multiple myeloma, according to updated data from a Phase 3 clinical trial.

Survival outcomes for people with multiple myeloma have improved substantially over the last two decades, likely due to the availability of new, more effective treatments, according to a population-based study from Germany. Myeloma itself was the most common cause of death. But the new data also showed that people…

The U.S. Food and Drug Administration (FDA) has agreed to review an application that, if approved, would allow the cell therapy Abecma (idecabtagene vicleucel) to be given earlier to people with hard-to-treat multiple myeloma. An FDA decision is expected by Dec. 16, according to Abecma’s developers…

The U.S. Food and Drug Administration (FDA) has given a fast track designation to CB-011, an experimental CAR T-cell therapy being developed by Caribou Biosciences for people with relapsed or refractory multiple myeloma. Fast track status is given to investigational treatments with the potential to fill an…

More than a dozen new mouse models of multiple myeloma, which researchers hope will advance understanding and treating the disease, were described in a new study. “We have generated artificial mice that accurately reflect key aspects of the origin and development of multiple myeloma in humans,” Marta Larráyoz, the…

Blocking the activity of a group of proteins called fatty acid-binding proteins (FABPs) may be a useful treatment strategy for multiple myeloma, a new study shows. “We’ve found that blocking the FABPs can prevent the growth of myeloma cells, mainly by slowing the cells’ proliferation [growth rate],” Michaela Reagan,…

Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory multiple myeloma. “We look forward to working closely with the FDA in their review of the talquetamab submission,” Peter Lebowitz, MD, PhD, global oncology…

The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what has been reported in clinical trials, according to a study from Israel. “Response rate, duration of response and toxicity profile appear to be comparable to…

An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient evidence to support Pepaxto (melphalan flufenamide) as a treatment for relapsed or refractory multiple myeloma (RRMM). Notably, while the FDA will consider the committee’s…